We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Kit Distinguishes Between HSV-1 and HSV-2 in Vaginal Specimens

By LabMedica International staff writers
Posted on 01 Jun 2010
Qualitative detection of Herpes simplex virus (HSV) types 1 or 2 is based on the polymerase chain reaction (PCR). More...
Results are available in approximately four hours.

The HSV 1&2 kit utilizes MultiCode-RTx technology based on the company's novel synthetic DNA base pair (nucleotide): isoC:isoG. Not only are the isoC and isoG specific to each other, they are recognized by the enzyme used for PCR. This probe free chemistry provides significant ease-of-use and workflow advantages.

MultiCode-RTx uses PCR to amplify and then detect target DNA sequences. If a specific target sequence is present, PCR amplification will occur. During the amplification process, MultiCode directs the PCR enzyme to insert a fluorescence quencher directly opposite a reporter dye resulting in a decrease of fluorescence with every PCR cycle. The decrease is easily monitored by real-time PCR instruments.

EraGen Biosciences Inc. (Madison, WI, USA) announced that the U.S. Food and Drug Administration (FDA; Silver Springs, MD, USA) has granted 510(k) market clearance for the company's MultiCode-RTx HSV 1&2 Kit. The assay is not intended to be used for male penile specimens, for prenatal screening, or for females under the age of 18 years.

"EraGen's HSV 1&2 kit is the first FDA-cleared, molecular test for the Herpes simplex virus. It has considerable advantages over the traditional testing methodologies used today for the detection and typing of the virus in symptomatic women,” said Irene Hrusovsky, M.D., president and chief executive of EraGen.

Herpes simplex viruses cause oral and genital herpes infections. In immunocompromised individuals and infants, they can cause central nervous system disorders, blindness, liver disease, brain infections, and other illnesses.

EraGen Biosciences develops, manufactures, and markets innovative molecular diagnostic products. The company's in-market and pipeline products, based on MultiCode platform chemistry, are the next generation of DNA- and RNA-based testing for the early detection of infectious diseases and genetic conditions.

Related Links:
EraGen Biosciences Inc.
U.S. Food and Drug Administration


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.